Volume 30, Number 8—August 2024
Dispatch
Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody
Eisuke Adachi1
, Ayako Sedohara1, Kotaro Arizono, Kazuaki Takahashi, Amato Otani, Yoshiaki Kanno, Makoto Saito, Michiko Koga, and Hiroshi Yotsuyanagi
, Ayako Sedohara1, Kotaro Arizono, Kazuaki Takahashi, Amato Otani, Yoshiaki Kanno, Makoto Saito, Michiko Koga, and Hiroshi Yotsuyanagi
Table 3
Results of HBV DNA genome analysis on HBV strain isolated during hepatitis B reactivation in a person with HIV after changing antiretroviral therapy regimen to cabotegravir/rilpivirine*
| Category |
Region |
||||
| S gene |
P gene |
Pre-S1/pre-S2/S |
X gene |
Precore/core |
|
| Position | 155–835 | 2307–3221, 1–1623 | 2854–3221, 1–835 | 1374–1838 | 1814–2458/1901–2458 |
| Size, bp |
681 |
2538 |
1203 |
465 |
645 |
| Mutations | |||||
| Vaccine-escape | E164V | NA | NA | NA | NA |
| Drug-resistant | NA | ND | NA | NA | NA |
| Promoter | NA | NA | NA | NA | ND |
| Other | NA | NA | ND | ND | T1858C,† T1674C† |
*The full length of the HBV isolate was 3,221 bp. HBV, hepatitis B virus; NA, not applicable; ND, not detected. †These mutations are typically observed in genotype A2.
1These first authors contributed equally to this article.
Page created: June 28, 2024
Page updated: July 21, 2024
Page reviewed: July 21, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.